Kimberly N. Burgos Villar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kimberly N. Burgos Villar has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Eric M. Small
Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
2 shared publications - Adwiteeya Misra
Department of Medicine, Aab Cardiovascular Research Institute, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA
1 shared publication - Adwiteeya Misra
Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry (E.H.M., D.A.Z., K.N.B.V., D.M.M., A.M., R.A.D., E.M.S.).
1 shared publication - Cameron Baker
Genomic Research Center, University of Rochester Medical Center, Rochester, NY 14642, USA
1 shared publication - Daniel A. Zuppo
Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry (E.H.M., D.A.Z., K.N.B.V., D.M.M., A.M., R.A.D., E.M.S.).
1 shared publication - Deanne M. Mickelsen
Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine and Dentistry, NY. (D.D.H., A.C.B., R.A.D., D.M.M., E.M.S.)
1 shared publication
Latest Publications
- 31 March 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (13) , 1001-1004
Transient Sprr1a Expression Defines a Population of Border Zone Cardiomyocytes That Survive Ischemic Injury
- 31 March 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (13) , 1001-1004
Transient Sprr1a Expression Defines a Population of Border Zone Cardiomyocytes That Survive Ischemic Injury
- Open Access
- 12 December 2025
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (2) , 345-349
Immunotyping as an Alternative to Reducing Agents for Resolving Monoclonal Immunoglobulin Aggregates Observed on Immunofixation
Background: Polymerized immunoglobulins can be difficult to interpret when observed on serum immunofixation electrophoresis (IFE). The use of reducing agents, such as beta-mercaptoethanol (BME), has been instrumental in resolving cases in which the monoclonal protein is unidentifiable due to polymerization. However, this procedure can be inconvenient to laboratories. We therefore investigated the use of immunotyping (IT) to resolve immunoglobulin aggregates as a potential replacement for BME pretreatment. Methods: Patient samples with paraprotein polymerization were selected from our routine testing and interpretation workflow in the protein immunology laboratory. Identified specimens were subjected to both repeat IFE testing after BME treatment and IT without BME treatment. Results from both types of repeat testing were compared to each other and to patient history if available. IFE was performed on a Hydrasys 2 (Sebia), and IT was performed on a Capillarys 3 Tera (Sebia). Results: Five patient samples were identified with an aggregate band visible in all IFE lanes. Results of BME treatment with repeat IFE or IT using the original sample were 100% concordant. One patient was determined to have no monoclonal protein, 3 had immunoglobulin M (IgM) lambda monoclonal proteins, and one had an IgM kappa monoclonal protein. Conclusions: IT was able to successfully identify paraproteins without the use of BME in samples that were difficult to interpret using IFE due to polymerization. This finding suggests that routine protocols for IT can be used in lieu of a secondary protocol and additional resources for BME treatment prior to IFE analysis.
- 12 December 2025
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (2) , 345-349
Open AccessImmunotyping as an Alternative to Reducing Agents for Resolving Monoclonal Immunoglobulin Aggregates Observed on Immunofixation
Background: Polymerized immunoglobulins can be difficult to interpret when observed on serum immunofixation electrophoresis (IFE). The use of reducing agents, such as beta-mercaptoethanol (BME), has been instrumental in resolving cases in which the monoclonal protein is unidentifiable due to polymerization. However, this procedure can be inconvenient to laboratories. We therefore investigated the use of immunotyping (IT) to resolve immunoglobulin aggregates as a potential replacement for BME pretreatment. Methods: Patient samples with paraprotein polymerization were selected from our routine testing and interpretation workflow in the protein immunology laboratory. Identified specimens were subjected to both repeat IFE testing after BME treatment and IT without BME treatment. Results from both types of repeat testing were compared to each other and to patient history if available. IFE was performed on a Hydrasys 2 (Sebia), and IT was performed on a Capillarys 3 Tera (Sebia). Results: Five patient samples were identified with an aggregate band visible in all IFE lanes. Results of BME treatment with repeat IFE or IT using the original sample were 100% concordant. One patient was determined to have no monoclonal protein, 3 had immunoglobulin M (IgM) lambda monoclonal proteins, and one had an IgM kappa monoclonal protein. Conclusions: IT was able to successfully identify paraproteins without the use of BME in samples that were difficult to interpret using IFE due to polymerization. This finding suggests that routine protocols for IT can be used in lieu of a secondary protocol and additional resources for BME treatment prior to IFE analysis.
- Open Access
- 21 December 2021
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (1) , 1
Characterizing Neonatal Heart Maturation, Regeneration, and Scar Resolution Using Spatial Transcriptomics
The neonatal mammalian heart exhibits a remarkable regenerative potential, which includes fibrotic scar resolution and the generation of new cardiomyocytes. To investigate the mechanisms facilitating heart repair after apical resection in neonatal mice, we conducted bulk and spatial transcriptomic analyses at regenerative and non-regenerative timepoints. Importantly, spatial transcriptomics provided near single-cell resolution, revealing distinct domains of atrial and ventricular myocardium that exhibit dynamic phenotypic alterations during postnatal heart maturation. Spatial transcriptomics also defined the cardiac scar, which transitions from a proliferative to secretory phenotype as the heart loses regenerative potential. The resolving scar is characterized by spatially and temporally restricted programs of inflammation, epicardium expansion and extracellular matrix production, metabolic reprogramming, lipogenic scar extrusion, and cardiomyocyte restoration. Finally, this study revealed the emergence of a regenerative border zone defined by immature cardiomyocyte markers and the robust expression of Sprr1a. Taken together, our study defines the spatially and temporally restricted gene programs that underlie neonatal heart regeneration and provides insight into cardio-restorative mechanisms supporting scar resolution.
- 21 December 2021
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (1) , 1
Open AccessCharacterizing Neonatal Heart Maturation, Regeneration, and Scar Resolution Using Spatial Transcriptomics
The neonatal mammalian heart exhibits a remarkable regenerative potential, which includes fibrotic scar resolution and the generation of new cardiomyocytes. To investigate the mechanisms facilitating heart repair after apical resection in neonatal mice, we conducted bulk and spatial transcriptomic analyses at regenerative and non-regenerative timepoints. Importantly, spatial transcriptomics provided near single-cell resolution, revealing distinct domains of atrial and ventricular myocardium that exhibit dynamic phenotypic alterations during postnatal heart maturation. Spatial transcriptomics also defined the cardiac scar, which transitions from a proliferative to secretory phenotype as the heart loses regenerative potential. The resolving scar is characterized by spatially and temporally restricted programs of inflammation, epicardium expansion and extracellular matrix production, metabolic reprogramming, lipogenic scar extrusion, and cardiomyocyte restoration. Finally, this study revealed the emergence of a regenerative border zone defined by immature cardiomyocyte markers and the robust expression of Sprr1a. Taken together, our study defines the spatially and temporally restricted gene programs that underlie neonatal heart regeneration and provides insight into cardio-restorative mechanisms supporting scar resolution.